Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
1,104.34
-5.60 (-0.50%)
At close: Nov 26, 2025, 4:00 PM EST
1,104.10
-0.24 (-0.02%)
After-hours: Nov 26, 2025, 7:59 PM EST
Eli Lilly Revenue
Eli Lilly had revenue of $17.60B in the quarter ending September 30, 2025, with 53.87% growth. This brings the company's revenue in the last twelve months to $59.42B, up 45.41% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$59.42B
Revenue Growth
+45.41%
P/S Ratio
16.69
Revenue / Employee
$1,264,251
Employees
47,000
Market Cap
988.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
LLY News
- 9 hours ago - Stock Split Watch: Is Eli Lilly Next? - The Motley Fool
- 13 hours ago - Wall Street Breakfast Podcast: HP Downsizes To Power Up - Seeking Alpha
- 2 days ago - Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium - PRNewsWire
- 2 days ago - This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000? - The Motley Fool
- 2 days ago - Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting - PRNewsWire
- 2 days ago - Eli Lilly Stock Joins $1 Trillion Club: What Is Happening? - Forbes
- 2 days ago - Eli Lilly: Moving To 'Strong Buy' Rating On Revenue Growth Beyond Zepbound - Seeking Alpha
- 3 days ago - 2 Top Dividend Stocks for Growth-Oriented Investors - The Motley Fool